Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

Journal of Neurology, Neurosurgery, and Psychiatry
K RockwoodD Wilkinson

Abstract

To assess the efficacy and safety of galantamine in Alzheimer's disease at 3 months using flexible dose escalation. A randomised, double blind, placebo controlled trial in 43 centres in the United States, Canada, Great Britain, South Africa, Australia, and New Zealand. Patients with probable Alzheimer's disease (n=386; 171 women) with a score of 11-24 on the mini mental state examination, and a score> or =12 on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog) were randomised to placebo, or galantamine escalated over 4 weeks to a maintenance dose of 24 or 32 mg/day. The primary outcome measures were the change in ADAS-cog score and the clinician's interview based impression of change plus caregiver input (CIBIC-plus) score. Activities of daily living (ADL) and behavioural symptoms were secondary outcomes. To compare the effects of highest levels of dosing, an observed cases (OC) analysis was undertaken, with classic intention to treat (ITT) and ITT with last observation carried forward (LOCF) as confirmatory analyses. At 3 months, galantamine (24-32 mg/day) produced a significantly better outcome on cognitive function than placebo (treatment difference=1.9 points on ADAS-cog, p=0.002) and a significa...Continue Reading

References

Apr 16, 1986·Brain Research·P J WhitehouseK J Kellar
Jun 1, 1985·Neurology·L L BarclayJ Sansone
Jul 30, 1982·Science·R T BartusA S Lippa
Apr 6, 1994·JAMA : the Journal of the American Medical Association·M J KnappS I Gracon
Apr 6, 1994·JAMA : the Journal of the American Medical Association·P B WatkinsK W Lewis
Aug 28, 1996·JAMA : the Journal of the American Medical Association·C BeggD F Stroup
Jul 23, 1998·Neurology·M R Farlow, R M Evans
Sep 2, 1998·Psychopharmacology·E D Levin, B B Simon
Mar 10, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·P T FrancisG K Wilcock
Apr 24, 1999·BMJ : British Medical Journal·T Bayer
May 15, 1999·Dementia and Geriatric Cognitive Disorders·A BurnsL T Friedhoff
Jun 16, 1999·Archives of Neurology·W Pryse-Phillips
Sep 29, 1999·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·I GélinasS Gauthier

❮ Previous
Next ❯

Citations

Jul 16, 2003·Clinical Therapeutics·Timo ErkinjunttiUNKNOWN GAL-INT-6 Study Group
Jul 16, 2003·Clinical Therapeutics·Kristen Migliaccio-WalleUNKNOWN AHEAD Study Group
Jun 10, 2003·Alzheimer Disease and Associated Disorders·Sultan DarveshEarl Martin
Sep 27, 2003·Alzheimer Disease and Associated Disorders·Jan MarcussonSusanne Schwalen
Jul 14, 2004·Alzheimer Disease and Associated Disorders·Howard Fillit, Jerrold Hill
Jul 14, 2004·Alzheimer Disease and Associated Disorders·Rafael Blesa
Jul 14, 2004·Alzheimer Disease and Associated Disorders·Bengt Winblad, Vesna Jelic
Nov 5, 2004·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·T PirttiläC V Damaraju
Aug 6, 2005·BMJ : British Medical Journal·Hanna KaduszkiewiczHendrik van den Bussche
Apr 20, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·K Rockwood
Jul 2, 2005·Dementia and Geriatric Cognitive Disorders·Henry BrodatyChandrasekhar Rao V Damaraju
Apr 28, 2004·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Celio Levyman
Jul 24, 2003·Drugs & Aging·Gordon WilcockUNKNOWN GAL-GBR-2 Study Group
Mar 2, 2006·Drugs & Aging·Carlo CaltagironeUNKNOWN Italian Association of Psychogeriatrics
Dec 17, 2003·Clinical Pharmacokinetics·Martin R Farlow
Aug 17, 2006·Primary Care Companion to the Journal of Clinical Psychiatry·Frederick A Schmitt, Christine H Wichems
Jul 4, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·David S Geldmacher
Mar 22, 2006·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·W Nathan Rawls
Jan 18, 2008·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Lisa J Miller
Dec 20, 2007·Expert Review of Neurotherapeutics·George Razay, Gordon K Wilcock
Feb 2, 2010·Expert Opinion on Drug Metabolism & Toxicology·David PrvulovicJohannes Pantel
Jul 2, 2003·Expert Opinion on Investigational Drugs·Edith G McGeer, Patrick L McGeer
Nov 29, 2007·Expert Opinion on Investigational Drugs·Mercedes VillarroyaManuela G López
Nov 5, 2003·Current Medical Research and Opinion·Mark C DaleM Richardson
Nov 13, 2004·Current Medical Research and Opinion·J-M OrgogozoS Schwalen
Feb 7, 2015·Geriatrics & Gerontology International·Kosuke MatsuzonoKoji Abe
Jan 5, 2011·Journal of Psychosomatic Research·Diana E ClarkeRobert S Marin
Jul 14, 2009·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Kaori ItoUNKNOWN Alzheimer's Disease Working Group
Nov 26, 2015·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Andreas StröhleNina Rieckmann
Mar 4, 2003·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Jeffrey L Cummings
Oct 14, 2006·Mayo Clinic Proceedings·Martin R Farlow
Jul 16, 2008·Journal of Clinical Epidemiology·P E LeeG M Anderson
Apr 19, 2008·Lancet Neurology·Bruno VellasUNKNOWN European Task Force Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.